Healthcare Providers and Services
Company Overview of Boston Children's Hospital
Boston Children's Hospital provides pediatric health care services. The hospital provides surgical, radiological examination, and clinical and cancer research services. Additionally, it offers diabetes, endocrinology, gastroenterology, urology, neonatology, orthopedics, and pulmonology healthcare services. The hospital also provides community service programs and postdoctoral training services. Boston Children's Hospital was founded in 1869 and is based in Boston, Massachusetts. Boston Children's Hospital operates as a subsidiary of Children's Medical Center Corporation.
300 Longwood Avenue
Boston, MA 02115
Founded in 1869
Key Executives for Boston Children's Hospital
Chief Operating Officer and Executive Vice President of Health Affairs
Senior Vice President and Chief Information Officer
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2013.
Boston Children's Hospital Key Developments
Pollack Solomon Duffy LLP Announces Lawsuit Against Children's Hospital Boston for Confining 14 Year Old Girl Away from Her Mother
Nov 6 13
Pollack Solomon Duffy LLP announced a lawsuit filed in Suffolk County Superior Court against Children's Hospital Boston and several of its healthcare providers, by the Swiss mother of a 14 year-old girl allegedly confined for six weeks in 2012, separated from her mother and inadequately protected from a Haverhill woman allegedly the source of Xanax on which the girl overdosed. When finally discharging the girl, Children's Hospital returned her to the woman whose Xanax was the source of the overdose. Approximately six months passed before Claudia Felder, the girl's mother, recovered her daughter through a petition in Federal Court in Massachusetts under the Hague Convention on the Civil Aspects of International Child Abduction. A Federal trial proceeded in December 2012 and January 2013, resulting in a return of the girl to Felder in Switzerland. Felder's lawsuit alleges that Children's Hospital failed to create a safe environment for her daughter, free of influence from the woman whose Xanax was taken. According to the complaint, the hospital failed to reasonably cooperate with Felder, as the girl's sole legal custodian, to return her to Switzerland for safe care by appropriate medical professionals and her family. Felder alleges that Children's Hospital ignored information it had and red flags including that the Haverhill woman had been prescribed various medicines that can be associated with mental health issues, such as Concerta, Ritalin, Wellbutrin, Neurontin, Xanax, Klonopin and Ambien. Felder further alleges that Children's Hospital failed to consider discrepancies among the Haverhill woman's reports and other accounts about what transpired. As alleged, when Felder refused to pay for services while demanding her daughter's return to Switzerland, Children's Hospital supported the Haverhill woman's efforts to separate the girl and her mother. The civil action includes claims for negligence, interference with custody rights, and loss of filial consortium. In another civil action involving an international child abduction, on August 23, 2013, another client of Pollack Solomon Duffy LLP won an award of $40,250,000 from Federal Judge Richard Stearns in Massachusetts based on claims that a parent had been separated from children.
Boston Children's Hospital and Abwiz Bio Partner to Improve the Diagnosis of Kawasaki Disease
Oct 25 13
Boston Children's Hospital and Abwiz Bio have signed a partnership agreement to develop a prototype test kit to diagnose Kawasaki Disease. The goal of the partnership between Boston Children's and Abwiz is to pair Boston Children's clinical resources, scientific expertise and Technology Development Fund program with Abwiz Bio's antibody technology platform to develop a rapid, accurate point-of-care test for Kawasaki Disease.
Boston Children's Hospital Launches Phase I Clinical Trial of Long-Lasting Local Anesthetic Derived from Cyanobacteria
Aug 27 13
Boston Children's Hospital has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for neosaxitoxin, a new local anesthetic derived from cyanobacteria being developed in partnership with Proteus SA, of Santiago, Chile. With the IND approval in hand, the hospital has launched a Phase I clinical study in healthy volunteers. In prior clinical testing carried out in Chile, neosaxitoxin was shown to provide local anesthesia for more than 24 hours following laparoscopic gall bladder removal. The current trial will provide more refined dose escalation and safety data in line with FDA standards, using neosaxitoxin produced by Proteus through an inexpensive, proprietary and GLP-compliant production and purification methodology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|